Home » India Gives FDC Makers 90 Days to Justify Product Safety, Efficacy

India Gives FDC Makers 90 Days to Justify Product Safety, Efficacy

November 16, 2016

Pharmaceuticals Regulatory Affairs

India is giving drugmakers of unapproved combination products more time to justify their manufacturing and marketing of the drug in the country.

To View This Article:

Login

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements